4,455 reports of this reaction
3.7% of all SITAGLIPTIN reports
#1 most reported adverse reaction
BLOOD GLUCOSE INCREASED is the #1 most commonly reported adverse reaction for SITAGLIPTIN, manufactured by Merck Sharp & Dohme LLC. There are 4,455 FDA adverse event reports linking SITAGLIPTIN to BLOOD GLUCOSE INCREASED. This represents approximately 3.7% of all 119,503 adverse event reports for this drug.
SITAGLIPTIN has an overall safety score of 78 out of 100. Patients taking SITAGLIPTIN who experience blood glucose increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLOOD GLUCOSE INCREASED is moderately reported among SITAGLIPTIN users, representing a notable but not dominant share of adverse events.
In addition to blood glucose increased, the following adverse reactions have been reported for SITAGLIPTIN:
The following drugs have also been linked to blood glucose increased in FDA adverse event reports:
BLOOD GLUCOSE INCREASED has been reported as an adverse event in 4,455 FDA reports for SITAGLIPTIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLOOD GLUCOSE INCREASED accounts for approximately 3.7% of all adverse event reports for SITAGLIPTIN, making it one of the most commonly reported side effect.
If you experience blood glucose increased while taking SITAGLIPTIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.